Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CNTX-0290 in Healthy Subjects
NCT05341102Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ly3556050 in chronic pain (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events, Maximum Concentration and 4 more. Started Sep 2016; status: completed.
02
Drugs
ly3556050
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT05341102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341102.